secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001730463-24-000132
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus Therapeutics Q3 net loss $82M; FDA approval of AUCATZYL triggers $30M milestone
--------------------------------------------------------------------------------

- FDA approved AUCATZYL (obe-cel) for adult r/r B-ALL on Nov 8, 2024, ahead of PDUFA date.
- FDA approval triggers $30M milestone payment from Blackstone to Autolus.
- Cash and equivalents totaled $657.1M at Sep 30, 2024, up from $239.6M at Dec 31, 2023.
- Net loss of $82.1M for Q3 2024 vs $45.8M in Q3 2023; diluted EPS -$0.31.
- Matthias Will M.D. appointed Chief Development Officer effective Sep 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/0001730463-24-000132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000132/autl-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer